Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.675
Bid: 1.65
Ask: 1.70
Change: 0.00 (0.00%)
Spread: 0.05 (3.03%)
Open: 1.675
High: 1.725
Low: 1.625
Prev. Close: 1.675
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

30 Apr 2010 09:42

RNS Number : 1189L
Epistem Holdings plc
30 April 2010
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

Epistem Holdings plc

 

 

 

 

 

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation: iii

Octopus Investments Nominees Limited

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date on which the threshold is crossed or reached: v

16/04/10

6. Date on which issuer notified:

29/04/10

7. Threshold(s) that is/are crossed or reached: vi, vii

4%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00B1VKB244

 

364300

 

364300

 

315000

 

315000

 

3.97%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

315000

 

3.97%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

 

N/A

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

14. Contact name:

Russell Jarvis

15. Contact telephone number:

020 7710 8653

 

Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Peter Orsi

Contact address

(registered office for legal entities)

 

8 Angel Court, London, EC2R 7HP

Phone number & email

 

020 7710 8653

Other useful information

(at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

 

Contact address

 

Phone number & email

 

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUROWRRWASORR
Date   Source Headline
4th Mar 20203:33 pmRNSGrant of options
13th Feb 20209:53 amRNSHolding(s) in Company
11th Feb 20204:00 pmRNSDirector/PDMR Shareholding
6th Feb 20204:30 pmRNSHolding(s) in Company
5th Feb 20205:38 pmRNSDirector/PDMR Shareholding
5th Feb 20205:32 pmRNSDirector/PDMR Shareholding
5th Feb 20204:45 pmRNSHolding(s) in Company
5th Feb 20207:15 amEQSHardman & Co Research: genedrive plc (GDR): Western market progress but developing markets difficult
4th Feb 20204:25 pmRNSDirector/PDMR Shareholding
4th Feb 20202:06 pmRNSSecond Price Monitoring Extn
4th Feb 20202:00 pmRNSPrice Monitoring Extension
4th Feb 20207:00 amRNSHalf-year Report
15th Jan 20207:00 amRNSNotice of Results
11th Dec 20195:24 pmRNSHolding(s) in Company
11th Dec 201910:06 amRNSHolding(s) in Company
5th Dec 201911:30 amRNSAdditional Listing
3rd Dec 20197:00 amRNSAIHL assay kit demonstrates high clinical accuracy
27th Nov 20194:23 pmRNSResult of AGM
22nd Nov 20192:41 pmRNSDirector/PDMR Shareholding
21st Nov 201912:30 pmEQSHardman & Co Research: genedrive plc (GDR): Regulatory hurdle leaped: hearing loss assay
18th Nov 20197:00 amRNSAntibiotic Induced Hearing Loss Assay CE marking
6th Nov 20197:00 amRNSNotice of AGM and Change of Auditors
28th Oct 20197:30 amEQSHardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected
22nd Oct 20193:07 pmRNSHolding(s) in Company
22nd Oct 20193:06 pmRNSHolding(s) in Company
7th Oct 20197:00 amRNSNHS Ethics approval for use of AIHL test in trials
3rd Oct 20197:00 amRNSFinal Results
9th Sep 20197:00 amRNSNotice of Results
18th Jul 20197:30 amEQSHardman & Co Research: genedrive plc (GDR): Hepatitis C market frustrations
18th Jul 20197:00 amRNSDirector/PDMR Shareholding
9th Jul 20197:00 amRNSTrading Update
8th Apr 201910:54 amEQSHardman & Co Research: genedrive plc (GDR): First commercial sales in new focus area: bio-threats
5th Apr 20198:29 amRNSDirector/PDMR Shareholding
28th Mar 20197:00 amRNSHalf-year Report
16th Jan 20191:21 pmRNSHolding(s) in Company
15th Jan 20197:00 amRNSTrading update
31st Dec 201811:30 amRNSResult of AGM
12th Dec 20187:49 amRNSHolding(s) in Company
11th Dec 20187:15 amEQSHardman & Co Research: genedrive plc (GDR): Accelerating into fiscal 2019 with first sales
10th Dec 20184:44 pmRNSHolding(s) in Company
10th Dec 20183:40 pmRNSHolding(s) in Company
10th Dec 201811:04 amRNSHolding(s) in Company
7th Dec 20183:07 pmRNS2018 Annual Report and AGM Notice
7th Dec 20182:59 pmRNSResult of GM
29th Nov 20187:00 amRNSAbbVie to use HCV assay in study
19th Nov 20183:27 pmRNSPosting of Shareholder Circular
16th Nov 20181:42 pmRNSResult of Equity Placing
16th Nov 20187:00 amRNSProposed Placing and Broker Option
16th Nov 20187:00 amRNSUnaudited Preliminary Results
10th Sep 20181:46 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.